Key facts
- This page summarizes Eric Dobmeier's Form 3 filing for Janux Therapeutics, Inc. (JANX).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 22 Jul 2024, 20:01.
Eric Dobmeier - 19 Jul 2024 Form 3 Insider Report for Janux Therapeutics, Inc. (JANX)
- Reporting relationship
- Director
- Issuer ticker
- JANX
- Reported as of
- 19 Jul 2024
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 22 Jul 2024, 20:01:51 UTC
- Prior SEC filing
- 27 Jun 2024
- Next SEC filing
- 01 May 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Pennington, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Eric Dobmeier filed Form 3 for Janux Therapeutics, Inc. (JANX) on 22 Jul 2024.
Change
- Previous filing in this sequence was filed on 27 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Additional SEC filing notes
Filing notes and footnotes
Ownership status
The filing reports no beneficially owned securities.